At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 5, 2026 at 16:05 ET
Profound Medical reported record Q4 and full-year 2025 results, with Q4 revenue up 43% YoY to $6.0 million, driven by strong capital equipment sales and recurring revenue. The company strengthened its balance sheet with a $42.45 million equity raise, expanded globally through new distribution deals, and launched AI-enhanced TULSA-AI for BPH. Despite revenue growth, net losses widened to $8.2M in Q4 and $42.6M for the year due to rising operating expenses.
- Q4 2025 revenue: $6.0 million, up 43% YoY ($4.2M in Q4 2024)
- Full-year 2025 revenue: $16.1 million vs. $10.7 million in 2024
- Gross margin: 67% in Q4 2025 (down from 71% YoY), 71% for full-year 2025 (up from 66%)
- Net loss: $8.2 million in Q4 2025 vs. $4.9 million in Q4 2024; $42.6 million for FY2025 vs. $27.8 million in FY2024
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access